Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 9/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 2/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5151087 | 0.95 | MALT1 (0.43) | ACHELMNAMAPTNTSR1HTT | |
| SCHEMBL5149259 | 0.89 | ACHE (0.49) | ACHELMNAMAPTNTSR1HTT | |
| SCHEMBL5149276 | 0.84 | ACHE (0.43) | ACHELMNAMAPTNTSR1HTT | |
| SCHEMBL5148959 | 0.83 | HRH3 (0.41) | SMN1; SMN2HRH3GAADRD2DRD4 | |
| SCHEMBL5149214 | 0.80 | MCHR1 (0.41) | SMN1; SMN2HRH3GAA | |
| SCHEMBL5149144 | 0.80 | LDHA (0.39) | MAPTHTTSMN1; SMN2KDM4E | |
| SCHEMBL5149119 | 0.78 | GSK3B (0.39) | ACHELMNAHTTSMN1; SMN2BCHE | |
| SCHEMBL5149173 | 0.78 | HTR7 (0.37) | — | |
| SCHEMBL5147973 | 0.77 | LDHA (0.42) | MAPTKMT2ANPSR1GBA1HRH3 | |
| SCHEMBL5149127 | 0.77 | ROCK1 (0.43) | BCHEHRH3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265120-B2 | Pyrazine derivatives and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | ADORA2A, HTR5A, ADORA1 | ACHE 33/4885LMNA 2809/4885MAPT 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.